Acute Mountain Sickness (AMS)
6
1
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
33%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude
Efficacy of Positive Expiratory Pressure on Acute Mountain Sickness
HighCycle Study: Acetazolamide, High Altitude and Plasma Volume
Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)
Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness